share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer BOERNER CHRISTOPHER S.

SEC announcement ·  Mar 13 07:59
Summary by Futu AI
On March 10, 2024, Christopher S. Boerner, Chief Executive Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Boerner acquired a total of 54,638 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 36,105 shares, with a portion of the disposals (13,975 shares) being used to cover exercise prices or tax liabilities at a price of $53.79 per share, resulting in a total market value of $1,043,902.53. Following these transactions, Boerner's direct holdings in Bristol-Myers Squibb common stock amounted to 101,205 shares.
On March 10, 2024, Christopher S. Boerner, Chief Executive Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Boerner acquired a total of 54,638 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 36,105 shares, with a portion of the disposals (13,975 shares) being used to cover exercise prices or tax liabilities at a price of $53.79 per share, resulting in a total market value of $1,043,902.53. Following these transactions, Boerner's direct holdings in Bristol-Myers Squibb common stock amounted to 101,205 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.